Author

David Mossman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Abdul MannaniD· 1 shared Alicia M. DouglasiD· 1 shared Andrew H. WeiiD· 1 shared Anoop Kumar EnjetiiD· 1 shared Brett NixoniD· 1 shared Bryce C. ThomasiD· 1 shared David Anthony Skerrett-ByrneiD· 1 shared Dilana Elisabeth StaudtiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdul MannanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling

Dilana Elisabeth Staudt, Zacary P. Germon, Abdul Mannan, Tabitha McLachlan, Heather C. Murray, Ryan J. Duchatel, Bryce C. Thomas, Tyrone S. Beitaki, Holly P. McEwen, Mika L. Persson, Leah Calvert, Izac J. Findlay, Evangeline R. Jackson, Nathan D. Smith, David Anthony Skerrett-Byrne, , Matthew D. Dun

This study identifies ATM-driven DNA repair and ROS addiction as mechanisms of resistance to FLT3 inhibitors in AML and shows ATM inhibition can overcome resistance in vitro and in vivo.

bioRxiv · Jul 26, 2024 · PreprintCancer Biology